

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Multiple Technology Appraisal

Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis ID6458

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Madrigal Pharmaceuticals	All Wales Therapeutics and Toxicology
(resmetirom)	Centre
Novo Nordisk Ltd (semaglutide)	Allied Health Professionals FederationBoard of Community Health Councils in
Patient/carer groups	Wales
All About Obesity	British National Formulary
British Liver Trust	Care Quality Commission
British Obesity Society	Department of Health - Northern Ireland
Diabetes UK	Healthcare Improvement Scotland
GUTS UK	Medicines and Healthcare products
HEART UK	Regulatory Agency
Hemochromotosis UK	National Association of Primary Care
Liver4Life	 National Pharmacy Association
LIVErNORTH	NHS Confederation
National Obesity Forum	NHS Wales Joint Commissioning
 Network of Sikh Organisations 	Committee
Obesity Empowerment Network	Scottish Medicines Consortium
Obesity Health Alliance	Welsh Government
Obesity UK	
 South Asian Health Foundation 	Possible comparator companies
Specialised Healthcare Alliance	Alliance Pharmaceuticals (vitamin E)
	Brown & Burk UK (pioglitazone)
Healthcare professional groups	Kora Healthcare (vitamin E)
 Association for the Study of Obesity 	Mylan (pioglitazone)
British Association for the Study of the	Neon Healthcare (pioglitazone)
Liver (BASL)	Sandoz (pioglitazone)
British Dietetic Association	
British Geriatrics Society	Relevant research groups
British Hepatology Pharmacy Group	Genomics England
British Nutrition Foundation	MRC Clinical Trials Unit
British Society for Paediatric	National Institute for Health Research
Endocrinology and Diabetes	
British Society of Gastroenterology	Associated Public Health groups
Faculty of Public Health	Public Health Wales
Hepatitis Nurse Specialist Forum	UK Health Security Agency

Provisional stakeholder list for the evaluation of resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis ID6458 Issue date: April 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Neonatal and Paediatric Pharmacists Group Nutrition Society Obesity Management Association Royal College of Emergency Medicine Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology UK Clinical Pharmacy Association 	
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis ID6458 Issue date: April 2025



Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.